EnteroBiotix
Agent43Agent Readiness: 43/100. Above median. Measured by StartupHub.ai. Median 41.Trust81Data Trust: 81/100. Top 25%. Measured by StartupHub.ai. Median 61.Developing microbiome-based therapeutics to address underlying disease biology, particularly in gastrointestinal health.
About this profileCompany details: from public sourcesFunding: no announced round on fileOwnership: not yet claimed by the companyScores: measured by named tools; each links to its methodOur rules
About
EnteroBiotix is a clinical-stage microbiome therapeutics company focused on transforming the standard of care for patients with gastrointestinal disease. Their lead investigational product, EBX-102-02, is an orally delivered, full-spectrum microbiome drug in clinical development for irritable bowel syndrome (IBS) and other gastrointestinal and liver-related diseases. EBX-102-02 is a high-diversity microbial product manufactured using proprietary AMPLA™ drying technology.
Listed competitors
Also in this space
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Pharmaceuticals
Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
Shares Biotechnology, Biotech
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Pharmaceuticals
A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.
Shares Biotechnology, Life Sciences
Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.
Shares Biotechnology, Healthcare
Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.
Shares Biotechnology, Drug Discovery
Key facts
- Website
- enterobiotix.com
- Headquarters
- Glasgow, United Kingdom
- Founded
- 2017
- Total funding
- $41M (Funding Round)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 4 May 2026 | Funding Round | $19M | Thairm Bio, Scottish National Investment Bank |
| 7 Sept 2021 | Series A | $22M |
Tech stack
Detected on enterobiotix.com, last scanned 29 Oct 2026. Run your own scan
- CMS / Builders
- Squarespace
- Email provider
- Barracuda
EnteroBiotix scores 30. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is EnteroBiotix trustworthy and reputable?
StartupHub's Data Trust & Reputation score for EnteroBiotix is 81 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has EnteroBiotix raised?
EnteroBiotix has raised a total of $41M in funding. The most recent round on record is Funding Round.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for EnteroBiotix
